Patent application number | Description | Published |
20080262081 | Novel Use of Nutraceutical Compositions Comprising Resveratrol - The use of resveratrol, a derivative, metabolite or analogue thereof, in combination with at least one additional component selected from EGCG, coenzyme Q-IO, genistein, lycopene, hydroxytyrosol and polyunsaturated fatty acids in the manufacture of a nutraceutical composition for delaying aging and/or for the treatment or prevention of age-related diseases in animals, in particular in mammals including humans. | 10-23-2008 |
20090131331 | Novel Nutraceutical Compositions - The present invention describes the use of MAP and/or ITP or a salt thereof as a nutraceutical, preferably a medicament. | 05-21-2009 |
20090163579 | Novel use of nutraceutical compositions - The use of at least one component selected from the group consisting of EGCG, hydroxytyrosol, resveratrol and derivatives, metabolites or analogues thereof in the manufacture of a nutraceutical composition for the prevention and treatment of muscle wasting leading to muscle loss, atrophy and other associated muscle disorders in animals, in particular mammals including humans. | 06-25-2009 |
20090192218 | USE OF PHTHALIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES MELLITUS - The present invention relates to the use of a compound as effective agent for the prevention or treatment of diabetes mellitus in a mammal. Said compounds being selected from the group of phthalide derivatives and exhibit excellent blood glucose lowering effects and thus are effective agents in the prevention or treatment of diabetes mellitus in mammals. | 07-30-2009 |
20090203773 | Compounds for the Treatment of Non-Autoimmune Type 2 Diabetes Mellitus and/or Syndrome X - The present invention relates to compounds of the formula (I); wherein R | 08-13-2009 |
20090221693 | NOVEL USE OF ORGANIC COMPOUNDS - The present invention refers to compounds of the general formulae I as defined above, preferably α-mangostin, for use as/in a composition (especially foods and dietary supplements, cosmetic, as well as pharmaceutical compositions) for the prevention and improvement of muscular disorders and for the improvement of muscle function and endurance. Other fields of use are eating disorders such as bulimia and anorexia nervosa, use for accelerating wound healing, and/or use for the treatment/prevention of bone disorders such as osteoporosis and osteopenia. The present invention is also directed to dietary compositions such as (fortified) food, beverages, (fortified) feed, food additives, beverage additives, feed additives, clinical nutrition, dietary supplements, functional food, functional feed and nutraceuticals and to pharmaceutical compositions containing such compounds, to methods of preventing and/or treating the above mentioned disorders/diseases, as well as to methods of maintaining the healthy state and/or improving the baseline conditions in mammals including humans and to the compounds of the formula I themselves. Another object of the present invention is the use of such compounds for the manufacture of a composition for the prevention and/or treatment of such disorders/diseases as mentioned above. | 09-03-2009 |
20090221694 | Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone - Compositions comprising epigallocatechin gallate and 4-(4-hydroxyphenyl)-2-butanone may be used for treatment or prevention of obesity or conditions associated with obesity such as non-insulin-dependent diabetes mellitus (NIDDM, type II) and syndrome X. The compositions may find use in the nutritional field as a supplement to food and beverages, as well as a pharmaceutical formulation. | 09-03-2009 |
20090239944 | Novel Use of Organic Compounds - The present invention relates to compounds of the formula I | 09-24-2009 |
20090305945 | NOVEL NUTRACEUTICAL COMPOSITIONS - The present invention describes a composition which comprises a protein hydrolysate or a protein hydrolysate and one amino acid hydrolysate for the long term treatment or prevention of type 2 diabetes or pre-diabetes or metabolic syndrome or obesity. | 12-10-2009 |
20100041746 | NOVEL USE OF ORGANIC COMPOUNDS - The present invention refers to compounds of the general formulae Ia to Ie as defined above for use as/in a composition (especially foods and dietary supplements, cosmetic, as well as pharmaceutical compositions) for the prevention and improvement of muscular disorders and for the improvement of muscle function. Other fields of use are disorders connected to impaired lipid metabolism, impaired glucose metabolism and impaired insulin action, obesity, overweight conditions, eating disorders such as bulimia and anorexia nervosa, cardiovascular diseases, atherosclerosis, vascular diseases, heart failure, inflammatory disorders such as arthritis, rheumatoid arthritis, osteoarthritis, gout, gastrointestinal disorders such as inflammatory bowel syndrome, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis, skin related conditions such as psoriasis, eczema, burns, dermatitis, and allergy, respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), allergic diseases, and/or bone disorders such as osteoporosis and osteopenia. The compounds may also be used for bodyshaping, for improving the muscle:fat ratio or for accelerating skin wound healing. The present invention is also directed to dietary compositions such as (fortified) food, beverages, (fortified) feed, food additives, beverage additives, feed additives, clinical nutrition, dietary supplements, functional food, functional feed and nutraceuticals and to pharmaceutical compositions containing such compounds, to methods of treating the above mentioned disorders/diseases in mammals including humans and to the compounds of the formula I themselves. Another object of the present invention is the use of such compounds for the manufacture of a composition for the treatment of such disorders/diseases as mentioned above. | 02-18-2010 |
20100113584 | NOVEL USE OF (-)-EPIGALLOCATECHIN GALLATE - Use of (−)-epigallocatechin gallate and/or one or more of its derivatives for increasing the desire, willingness and/or motivation of animals (including humans), especially mammals, to exercise, to perform and/or to run, especially to perform endurance exercise and furthermore to accelerate training success. | 05-06-2010 |
20110039809 | COMBINED USE OF 25-HYDROXY-VITAMIN D3 AND VITAMIN D3 FOR IMPROVING BONE MINERAL DENSITY AND FOR TREATING OSTEOPORISIS - We disclose the combined use of vitamin D (cholecalciferol) and 25-OH D3 (calcifediol) to treat and/or prevent osteoporosis. One or more bisphosphonate compounds to inhibit bone resorption may also be used. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 02-17-2011 |
20110039810 | USE OF 25-HYDROXY-VITAMIN D3 TO AFFECT HUMAN MUSCLE PHYSIOLOGY - We disclose the use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 02-17-2011 |
20110039811 | TREATING HYPERGLYCEMIA WITH 25-HYDROXYVITAMIN D3 - We disclose treating hyperglycemia in a human with 25-hydroxyvitamin D3 (calcifediol). Blood glucose is reduced to a level which is closer to normal than baseline. Vitamin D3 (cholecalciferol) may optionally be used together with 25-hydroxy vitamin D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 02-17-2011 |
20110052707 | COMBINATION OF VITAMIN D AND 25-HYDROXYVITAMIN D 3 - We disclose compositions comprising Vitamin D (cholecalciferol and/or ergocalciferol) and 25-OH D3 (calcifediol), and use of those compositions to affect at least concentration, bioavailability, metabolism, or efficacy of vitamin D in a human. Forms and dosages of the composition, as well as processes for manufacturing a spray-dried formulation, are also disclosed. | 03-03-2011 |
20110118218 | TREATING HYPERTENSION WITH 25-HYDROXYVITAMIN D3 - We disclose the use of optionally in combination with vitamin D3 (cholecalciferol), 25-hydroxyvitamin D3 (cal-cifediol), to treat hypertension. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 05-19-2011 |
20110142974 | TRIGONELLINE AS A MUSCLE STIMULANT - This invention relates to the use of trigonelline compounds to increase muscle weight during periods of activity or to inhibit muscle loss during periods of inactivity. | 06-16-2011 |
20110262612 | ROSEHIP POWDER HAVING SMALL PARTICLE SIZE - Rosehip powder has been finely ground such that it contains essentially no particles larger than 600 um when measured by laser diffraction. In one aspect of the invention (claim | 10-27-2011 |
20110300240 | CAJANUS EXTRACTS AND GLUCOSAMINE FOR INFLAMMATORY DISORDERS - The present invention relates to novel compositions comprising | 12-08-2011 |
20120190617 | NIACIN AND/OR TRIGONELLINE AS A MUSCLE STIMULANT - This invention relates to the use of niacin and/or trigonelline compounds to increase muscle weight during periods of activity or to inhibit muscle loss during periods of inactivity. | 07-26-2012 |
20120196057 | COMBINATION OF VITAMIN D AND 25-HYDROXYVITAMIN D 3 - We disclose compositions comprising Vitamin D (cholecalciferol and/or ergocalciferol) and 25-OH D3 (calcifediol), and use of those compositions to affect at least concentration, bioavailability, metabolism, or efficacy of vitamin D in a human. Forms and dosages of the composition, as well as processes for manufacturing a spray-dried formulation, are also disclosed. | 08-02-2012 |
20130018076 | TRIGONELLINE AS A MUSCLE STIMULANT - This invention relates to the use of trigonelline compounds to increase muscle weight during periods of activity or to inhibit muscle loss during periods of inactivity. | 01-17-2013 |
20130150598 | USE OF 25-HYDROXY-VITAMIN D3 TO AFFECT HUMAN MUSCLE PHYSIOLOGY - The use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both is provided. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 06-13-2013 |
20130210782 | TREATING HYPERGLYCEMIA WITH 25-HYDROXYVITAMIN D3 - We disclose treating hyperglycemia in a human with 25-hydroxyyitamin D3 (calcifediol). Blood glucose is reduced to a level which is closer to normal than baseline. Vitamin D3 (cholecalciferol) may optionally be used together with 25-hydroxy vitamin D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 08-15-2013 |
20150079206 | TRIGONELLINE AS A MUSCLE STIMULANT - This invention relates to the use of trigonelline compounds to increase muscle weight during periods of activity or to inhibit muscle loss during periods of inactivity. | 03-19-2015 |